BackLexicon Pharmaceuticals Overview

Lexicon Pharmaceuticals Receivables

Latest receivables for LXRX: $12M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$11.78M
75.17% YoYΔ $-35.67M vs prior year quarter

Peer average

Loading

Lexicon Pharmaceuticals Receivables History

Loading

Lexicon Pharmaceuticals vs. peers: Receivables Comparison

Loading

Lexicon Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Lexicon Pharmaceuticals (LXRX) FAQ

As of the most recent data (March 2026), LXRX shows a receivables of $12M. That compares with $47M in the prior-year period — down 75.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LXRX's receivables is now $12M (was $47M) — a 75.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Lexicon Pharmaceuticals is outperforming or lagging.

Tracking LXRX's receivables over time shows whether Lexicon Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $12M That compares with $47M in the prior-year period — down 75.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Lexicon Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $12M) with ownership activity and broader fundamentals.

Lexicon Pharmaceuticals's receivables is $12M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.